Product
Folfirinox
Aliases
Chemotherapy
5 clinical trials
3 indications
Indication
Pancreatic CancerIndication
Pancreatic Cancer MetastaticIndication
Pancreatic Ductal AdenocarcinomaClinical trial
A Phase I Open Label Followed by a Phase II Randomized, Controlled Study to Assess the Efficacy and Safety of ABTL0812 in Combination With FOLFIRINOX for First-line Treatment of Metastatic PancreaticStatus: Completed, Estimated PCD: 2024-01-10
Clinical trial
A Phase III Multicenter Open-label Randomized Trial to Evaluate Efficacy and Safety of Folfirinox (FFX) Versus Combination of CPI-613 With Modified Folfirinox (mFFX) in Patients With Metastatic Adenocarcinoma of the PancreasStatus: Completed, Estimated PCD: 2021-08-16
Clinical trial
Pancreatic Adenocarcinoma Signature Stratification for TreatmentStatus: Active (not recruiting), Estimated PCD: 2025-01-01
Clinical trial
An Adaptive Approach to Neoadjuvant Therapy to Maximize Resection Rates for Pancreatic Adenocarcinoma: A Phase II TrialStatus: Recruiting, Estimated PCD: 2024-05-01
Clinical trial
Phase II Study of Neoadjuvant Folfirinox Chemotherapy Followed by Pembrolizumab Followed by Surgery for Patients With Localized, Resectable Adenocarcinoma of the PancreasStatus: Recruiting, Estimated PCD: 2024-07-30